ETUDE ITALIENNE DE CHIMIOPREVENTION DU CANCER DU SEIN AVEC LE TAMOXIFENE

Translated title of the contribution: The Italian study of breast cancer chemoprevention with tamoxifen

U. Veronesi, A. Costa, V. Sacchini, A. Luini, B. Bonanni, P. Veronesi, N. Rotmensz, P. Boyle

Research output: Contribution to journalArticle

Abstract

There is currently a large breast cancer chemoprevention trial in Italy. The trial is based on the use of the antioestrogen tamoxifen, which is one of the most successful and most studied anticancer drugs. There is a strong evidence that this drug can prevent the growing of controlateral cancer in women previously operated for breast cancer. The chemoprevention trial using tamoxifen includes healthy women, aged 35 to 70 and hysterectomised. The participants are taking either 20 mg/day of tamoxifen or placebo for 5 years, in double blind; then they are followed-up clinically and instrumentally every 6 months for the further 5 years. The main end-point of the study is to verify the reduction of incidence and mortality from breast cancer. It was decided to recruit only hysterectomised women on the consideration that, according to some studies, tamoxifen could give an additional risk of endometrial cancer: the Italian study was especially designed with the intention of avoiding this unjustified risk.

Original languageFrench
Pages (from-to)258-260
Number of pages3
JournalContraception Fertilite Sexualite
Volume23
Issue number4
Publication statusPublished - 1995

    Fingerprint

Keywords

  • breast cancer
  • chemoprevention
  • tamoxifen

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this